Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported no revenue in Q4 2022 due to the discontinuation of commercial dermatology activities. For the full year, revenue reached $700,000, primarily from earlier in the year. Q4 GAAP expenses decreased to $8.7 million from $16.3 million YoY, while the net loss shrank to $9.2 million from $15.4 million. Total cash reserves increased to $61.1 million as of December 31, 2022, up from $28.6 million in 2021. The company is focused on developing NS PFA delivery devices for atrial fibrillation treatments, with a pre-submission meeting with the FDA planned for 2Q23.